API Product   :    Tofacitinib Citrate*
CEP   :    -
WCC   :    -
Therapeutic Use    :    Nonsteroidal products for inflammatory skin disorders; Immunosuppressants; Respiratory System; Anti-Inflammatory And Anti-Rheumatic Products
Originator   :    PFIZER
CAS No.    :    477600-75-2
Trade Name.   :    XELJANZ
Molecular Weight   :    312.369 g/mol
Molecular Formula   :    C16H20N6O
Tofacitinib is an oral drug used for treating rheumatoid arthritis. It belongs to a class of drugs called Janus kinase (JAK) inhibitors.
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.[1][2] Common side effects include diarrhea, headache, and high blood pressure.[1] Serious side effects may include infections and the development of cancer.[1] It is in the janus kinase (JAK) inhibitor class, discovered and developed by the National Institutes of Health and Pfizer.